Nabilone & Marijuana Addiction

Marijuana Smoking Clinical Trial

Official title:

A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01025700
• Other study ID #: H08-01999
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: December 2, 2009
• Last updated: February 16, 2011
• Start date: June 2009
• Est. completion date: October 2010

Study information

• Verified date: February 2011
• Source: University of British Columbia
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Safety of Nabilone in reducing marijuana craving

Description:

Randomized double blind trial into the safety and efficacy of Cesemat for the treatment of marijuana use

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: October 2010
• Est. primary completion date: June 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Years to 65 Years

Eligibility

Inclusion Criteria:

• 19 years or older

• History of marijuana use

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Marijuana Abuse
• Marijuana Smoking

Intervention

Drug:
• Cesemat
1 mg capsule per day for 21 days

Locations

Country	Name	City	State
Canada	Vancouver General Hospital - Psychiatry Outpatient	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability to Nabilone			No
Secondary	Marijuana craving questionnaire			No